ПРОДЛЕННАЯ ДВОЙНАЯ АНТИТРОМБОЦИТАРНАЯ ТЕРАПИЯ ПОСЛЕ ИНФАРКТА МИОКАРДА: О ЧЕМ ГОВОРЯТ РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ PEGASUS-TIMI 54
https://doi.org/10.20996/1819-6446-2017-13-4-558-564
Аннотация
Представлены предпосылки к продленному использованию двойной антитромбоцитарной терапии после инфаркта миокарда. Рассматриваются результаты крупного рандомизированного плацебо-контролируемого исследования PEGASUS-TIMI 54 по оценке эффективности и безопасности длительного применения сочетания ацетилсалициловой кислоты и блокатора P2Y12 рецептора тромбоцитов тикагрелора у больных с высоким риском тромботических осложнений атеросклероза, перенесших инфаркт миокарда 1-3 года назад. Анализируется вклад, который внесли результаты этого клинического исследования в современные представления об оптимальном использовании антиагрегантов у больных, перенесших инфаркт миокарда.
При поддержке: компания АстраЗенека
Об авторе
И. С. Явелов
Национальный медицинский исследовательский центр профилактической медицины
Россия
Россия
д.м.н., в.н.с., отдел клинической кардиологии и молекулярной генетики,
101000, Москва, Петроверигский пер., 10
Список литературы
1. Jernberg T., Hjelm H., Hasvold P., et al. Continued high CVD risk in myocardial infarction survivors: comparison of risk first and second year after MI - results from a Swedish nationwide study. Eur Heart J. 2014;35(suppl. 1):363.
2. Jernberg T., Hasvold P., Henriksson M., et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163-70.
3. Fox K.A.A., Carruthers K.F., Dunbar D.R., et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J. 2010;31:2755-64.
4. Cambou J.P., Simon T., Mulak G., et al, The French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction (FAST-MI): study design and baseline characteristics. Arch Mal Coeur Vaiss. 2007;100:524-34.
5. Stone G.W., Maehara A., Lansky A.J., et al.; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35.
6. Varenhorst C.,Johansson S., Hasvold P., et al. Culprit and Non-Culprit RecurrentIschemic Events in PostMyocardial Infarction Patients: Data From SWEDEHEART. Circulation. 2016;134:A13206.
7. Kereiakes D.J., Yeh R.W., Massaro J.M., et al. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. JACC. 2016;67:2492-502.
8. Mauri L., Kereiakes D.J., Yeh R.W., et al. Twelve or 30 months of dual antiplatelet therapy after drugeluting stents. N Engl J Med. 2014;371:2155-66.
9. Yeh R.W., Kereiakes D.J., Steg P.G., et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. JACC. 2015;65:2211-21.
10. Udell J.A., Bonaca M.P., Collet J.P., et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390-9.
11. Nakatani D., Sakata Y., Suna S., et al.; Osaka Acute Coronary Insufficiency Study (OACIS) Investigators. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circ J. 2013;77:439-46.
12. Figueras J., Missorici M., Lidón R.M., et al. Coincidental annual distribution of first and second acute myocardial infarction. Am J Cardiol. 2002;89:1416-20.
13. Nauta S.T., Deckers J.W., Akkerhuis K.M., et al. Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes. Changes from 1985 to 2008. Diabetes Care. 2012;35:2043-7.
14. Romain A., Elbaz M., Simon T., et al. Prevalence, clinical proёle and 3-year survival of acute myocardial infarction patients with and without obstructive coronary lesions: The FAST-MI 2005 registry. Int J Cardiol. 2014;172:e247-e249.
15. Bhatt D.L., Eagle K.A., Ohman E.M.; REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350-7.
16. Bonaca M.P., Bhatt D.L., Cohen M., et al., for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med. 2015;372:1791-800.
17. Bonaca M.P., Bhatt D.L., Steg P.G., et al. Ischaemic risk and efficacy of ticagrelorin relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37:1133-42.
18. Bonaca M.P., Goto S., Bhatt D.L., et al. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction. Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation. 2016;134:861-71.
19. Wallentin L., Becker R.C., Budaj A., et al., for the PLATO Investigators. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2009;361:1045-57.
20. Bhatt D.L., Bonaca M.P., Bansilal S., et al. Reduction in Ischemic Events with Ticagrelor in Diabetic Patients: From the PEGASUS-TIMI 54 Trial. JACC. 2016;67:2732-40.
21. Magnani G., Storey R.F., Steg G., et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37:400-8.
22. Bonaca M.P., Bhatt D.L., Storey R.F., et al. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. JACC. 2016;67:2719-28.
23. Bansilal S., Bonaca M., Cornel J.H., et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in patients with prior mi and multivessel coronary disease: insights from the PEGASUS-TIMI 54 trial. JACC. 2016;67:A2146.
24. Capodanno D., Capranzano P., Buccheri S., Tamburino C. Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial. Int J Cardiol. 2015;201:276-8.
25. Bonaca M.P., Bhatt D.L., Oude Ophuis T., et al. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol. 2016;1:425-32.
26. Roffi M., Patrono C., Collet J.P., et al. 2015ESCGuidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267-315.
27. Correction to: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable IschemicHeartDisease, 2013 ACCF/AHA Guideline forthe Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016 Sep 6;134(10):e192-4.
28. Bonaca M.P., Storey R.F, Theroux P., et al. Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54. Circulation. 2015;132:A19642.
Рецензия
Для цитирования:
Явелов И.С. ПРОДЛЕННАЯ ДВОЙНАЯ АНТИТРОМБОЦИТАРНАЯ ТЕРАПИЯ ПОСЛЕ ИНФАРКТА МИОКАРДА: О ЧЕМ ГОВОРЯТ РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ PEGASUS-TIMI 54. Рациональная Фармакотерапия в Кардиологии. 2017;13(4):558-564. https://doi.org/10.20996/1819-6446-2017-13-4-558-564
For citation:
Yavelov I.S. PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW. Rational Pharmacotherapy in Cardiology. 2017;13(4):558-564. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-4-558-564
Просмотров:
903
Послать статью по эл. почте 